Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysis.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  International Journal of Molecular Medicine

• Publication date

  2015-11-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.3892/ijmm.2015.2330PMID 26324422
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Astragaloside IV possesses antiarthritic effect by preventing interleukin 1β-induced joint inflammation and cartilage damage

  2014cited by this paper
• Fucoidan, a Sulfated Polysaccharide, Inhibits Osteoclast Differentiation and Function by Modulating RANKL Signaling

  2014cited by this paper
• Astragaloside IV attenuates allergic inflammation by regulation Th1/Th2 cytokine and enhancement CD4(+)CD25(+)Foxp3 T cells in ovalbumin-induced asthma.

  2014cited by this paper
• The effect of enoxacin on osteoclastogenesis and reduction of titanium particle-induced osteolysis via suppression of JNK signaling pathway.

  2014cited by this paper
• Genistein Inhibits Osteoclastic Differentiation of RAW 264.7 Cells via Regulation of ROS Production and Scavenging

  2014cited by this paper
• Astragalosides IV inhibits high glucose-induced cell apoptosis through HGF activation in cultured human tubular epithelial cells

  2014influential reference
• Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF‑κB pathway under high glucose conditions.

  2014cited by this paper
• The effect of metallic magnesium degradation products on osteoclast-induced osteolysis and attenuation of NF-κB and NFATc1 signaling.

  2014cited by this paper
• The deception and fallacies of sponsored randomized prospective double-blinded clinical trials: the bisphosphonate research example.

  2014cited by this paper
• An overview on the treatment of postmenopausal osteoporosis.

  2014cited by this paper
• Astragaloside IV inhibits doxorubicin-induced cardiomyocyte apoptosis mediated by mitochondrial apoptotic pathway via activating the PI3K/Akt pathway.

  2014cited by this paper
• Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression.

  2013cited by this paper
• Cost–effectiveness of denosumab in the treatment of postmenopausal osteoporotic women

  2013cited by this paper
• Xiang-Qi-Tang and its active components exhibit anti-inflammatory and anticoagulant properties by inhibiting MAPK and NF-κB signaling pathways in LPS-treated rat cardiac microvascular endothelial cells

  2013influential reference
• Preventive Effects of a Natural Anti-Inflammatory Agent, Astragaloside IV, on Ischemic Acute Kidney Injury in Rats

  2013cited by this paper
• Pharmacological effects of Astragaloside IV: a literature review.

  2013cited by this paper
• Sex and risk of hip implant failure: assessing total hip arthroplasty outcomes in the United States.

  2013cited by this paper
• Adenovirus-mediated small interfering RNA targeting tumor necrosis factor-α inhibits titanium particle-induced osteoclastogenesis and bone resorption.

  2013cited by this paper
• Lipopolysaccharide (LPS) promotes osteoclast differentiation and activation by enhancing the MAPK pathway and COX-2 expression in RAW264.7 cells.

  2013cited by this paper
• Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.

  2012cited by this paper
• V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.

  2012cited by this paper
• Astragaloside IV attenuates Toll-like receptor 4 expression via NF-κB pathway under high glucose condition in mesenchymal stem cells.

  2012cited by this paper
• Prevention of Wear Particle-Induced Osteolysis by a Novel V-ATPase Inhibitor Saliphenylhalamide through Inhibition of Osteoclast Bone Resorption

  2012cited by this paper
• Astragaloside IV Attenuates Complement Membranous Attack Complex Induced Podocyte Injury Through the MAPK Pathway

  2012influential reference
• Tanshinone IIA and astragaloside IV promote the migration of mesenchymal stem cells by up-regulation of CXCR4

  2012cited by this paper
• Potent inhibitory effect of Foeniculum vulgare Miller extract on osteoclast differentiation and ovariectomy-induced bone loss.

  2012cited by this paper
• Extracellular signal-regulated kinase 1/2-mediated phosphorylation of p300 enhances myosin heavy chain I/β gene expression via acetylation of nuclear factor of activated T cells c1

  2011cited by this paper
• The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.

  2011cited by this paper
• The osteogenetic effect of astragaloside IV with centrifugating pressure on the OCT-1 cells.

  2011cited by this paper
• Targeting extracellular signal-regulated kinase (ERK) signaling has therapeutic implications for inflammatory osteolysis.

  2010cited by this paper
• Proteomic characterization of the cellular response to chemopreventive triterpenoid astragaloside IV in human hepatocellular carcinoma cell line HepG2.

  2010cited by this paper
• Effect of Astragaloside IV on the General and Peripartum Reproductive Toxicity in Sprague-Dawley Rats

  2010cited by this paper
• Cellular and Molecular Mechanisms of Bone Remodeling*

  2010cited by this paper
• Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis

  2009cited by this paper
• ASTRAGALOSIDE IV ATTENUATES HYPOXIA‐INDUCED CARDIOMYOCYTE DAMAGE IN RATS BY UPREGULATING SUPEROXIDE DISMUTASE‐1 LEVELS

  2009cited by this paper
• Inhibition of titanium particle-induced osteoclastogenesis through inactivation of NFATc1 by VIVIT peptide.

  2009cited by this paper
• Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

  2009cited by this paper
• Suppression of NF-kappaB activation blocks osteoclastic bone resorption during estrogen deficiency.

  2008cited by this paper
• The molecular understanding of osteoclast differentiation.

  2007cited by this paper
• The cellular and molecular biology of periprosthetic osteolysis.

  2007cited by this paper
• Particle-Induced Osteolysis in Three-Dimensional Micro-Computed Tomography

  2007cited by this paper
• Estrogen Regulation of Immune Cell Bone Interactions

  2006cited by this paper
• Implant wear induces inflammation, but not osteoclastic bone resorption, in RANK–/– mice

  2006cited by this paper
• Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.

  2006cited by this paper
• Regulation of the Transcriptional Activity of c-Fos by ERK

  2005cited by this paper
• A new treatment for post-menopausal osteoporosis: strontium ranelate.

  2005cited by this paper
• Osteoclast differentiation and activation

  2003cited by this paper
• Phosphatidylinositol 3‐kinase coordinately activates the MEK/ERK and AKT/NFκB pathways to maintain osteoclast survival

  2003cited by this paper
• Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.

  2002cited by this paper
• Microphthalmia Transcription Factor Is a Target of the p38 MAPK Pathway in Response to Receptor Activator of NF-κB Ligand Signaling*

  2002cited by this paper
• Therapeutic approaches to bone diseases.

  2000cited by this paper
• Requirement for NF-kappaB in osteoclast and B-cell development.

  1997cited by this paper
• Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2.

  1997cited by this paper
• Requirement for NF-κB in osteoclast and B-cell development

  1997cited by this paper
• c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling.

  1994cited by this paper
• Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report

  1994cited by this paper
• Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells.

  1990cited by this paper

• Astragaloside IV attenuates glucocorticoid-induced osteoclastogenesis and bone loss via the MAPK/NF-κB pathway

  2025cites this paper
• The therapeutic potential of terpenes in periodontal disease: a systematic review of pre-clinical animal studies

  2025cites this paper
• Exploring the mechanism of action of astragaloside in the treatment of osteoarthritis based on network pharmacology

  2025cites this paper
• Critical signaling pathways in osteoclast differentiation and bone resorption: mechanisms and therapeutic implications for periprosthetic osteolysis

  2025cites this paper
• Natural products in rheumatoid arthritis: Cell type-specific mechanisms and therapeutic implications.

  2025cites this paper
• A comprehensive review of natural products in rheumatoid arthritis: therapeutic potential and mechanisms

  2025cites this paper
• Astragaloside IV alleviated bone loss in mice with ovariectomy-induced osteoporosis via modulating gut microbiota and fecal metabolism

  2025cites this paper
• Periprosthetic osteolysis: Mechanisms and potential treatment strategies.

  2025cites this paper
• The nano-artificial periosteum made of PCL/MgO/AS-IV enhances MC3T3-E1 cell osteogenic differentiation and promotes bone defect repair via the EphB4/EphrinB2 signaling pathway

  2024cites this paper
• Efficacy and Possible Mechanisms of Astragali Radix and its Ingredients in Animal Models of Osteoporosis: A Preclinical Review and Metaanalysis.

  2024cites this paper
• Effect of Ishophloroglucin A Isolated from Ishige okamurae on In Vitro Osteoclastogenesis and Osteoblastogenesis

  2023cites this paper
• Astragaloside-IV induces the differentiation of bone marrow mesenchymal stem cells into osteoblasts through NMUR2-mediated Wnt/β-catenin pathway.

  2023cites this paper
• The Role of TAK1 in RANKL-Induced Osteoclastogenesis

  2022cites this paper
• Alendronate modified mPEG-PLGA nano-micelle drug delivery system loaded with astragaloside has anti-osteoporotic effect in rats

  2022cites this paper
• Tetracycline-grafted mPEG-PLGA micelles for bone-targeting and osteoporotic improvement

  2022cites this paper
• ERK Inhibition Increases RANKL-Induced Osteoclast Differentiation in RAW 264.7 Cells by Stimulating AMPK Activation and RANK Expression and Inhibiting Anti-Osteoclastogenic Factor Expression

  2022cites this paper
• Astragaloside IV protects against iron loading‐induced abnormal differentiation of bone marrow mesenchymal stem cells (BMSCs)

  2021cites this paper
• Accelerated Bone Regeneration by Astragaloside IV through Stimulating the Coupling of Osteogenesis and Angiogenesis

  2021cites this paper
• Multiple versus Solitary Giant Cell Lesions of the Jaw: Similar or Distinct Entities?

  2021cites this paper
• The unfavorable role of titanium particles released from dental implants

  2021cites this paper
• Amaranthus mangostanus Inhibits the Differentiation of Osteoclasts and Prevents Ovariectomy-Induced Bone Loss

  2020cites this paper
• Astragaloside-IV modulates NGF-induced osteoblast differentiation via the GSK3β/β-catenin signalling pathway

  2020cites this paper
• DAPT inhibits titanium particle-induced osteolysis by suppressing the RANKL/Notch2 signaling pathway.

  2020cites this paper
• Inhibition of MEK/ERK upregulates GSH production and increases RANKL-induced osteoclast differentiation in RAW 264.7 cells

  2020cites this paper
• Astragaloside IV attenuates inflammatory injury and promotes odontoblastic differentiation in lipopolysaccharide-stimulated MDPC-23 cells and rat pulpitis.

  2019cites this paper
• Astragaloside IV promotes the proliferation and migration of osteoblast-like cells through the hedgehog signaling pathway

  2018cites this paper
• Inhibitory effects of cycloastragenol on abdominal aortic aneurysm and its related mechanisms

  2018cites this paper
• IL-13 and IL-13Rα1 are overexpressed in extranodal natural killer/T cell lymphoma and mediate tumor cell proliferation.

  2018cites this paper
• Small molecule inhibitor RepSox prevented ovariectomy‐induced osteoporosis by suppressing osteoclast differentiation and bone resorption

  2018cites this paper
• Astragaloside IV Alleviates Lipopolysaccharide-Induced Acute Kidney Injury Through Down-Regulating Cytokines, CCR5 and p-ERK, and Elevating Anti-Oxidative Ability

  2017cites this paper
• Systemic drugs that influence titanium implant osseointegration

  2017cites this paper
• Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis

  2017cites this paper